Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile Infection

Trial Profile

Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile Infection

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 05 Sep 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fidaxomicin (Primary)
  • Indications Clostridium difficile infections
  • Focus Therapeutic Use

Most Recent Events

  • 27 Aug 2018 Status changed from not yet recruiting to withdrawn prior to enrolment due to lost of funding.
  • 08 Jun 2018 Planned initiation date changed from 1 Feb 2018 to 1 Jul 2018.
  • 12 Jan 2018 Planned initiation date changed from 1 Oct 2017 to 1 Feb 2018.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top